Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus

Table 1

Comparison of clinical background between the effective group and ineffective group in all participants with type 2 diabetes.

Clinical parameter	Effective group	Ineffective group	value
Number	147	65
Gender (men/women); n (%)	90 (61)/57 (39)	36 (55)/29 (45)	N.S.
Age (year)	65.8 ± 10.5	61.1 ± 14.3	<0.05
BMI (kg/m^2)	25.1 ± 5.0	25.1 ± 5.5	N.S.
Duration of diabetes (year)	15.8 ± 9.6	13.5 ± 7.9	N.S.
Family history of diabetes (%)	60	49	N.S.
Baseline HbA1c (%) (mmol/mol)	7.8 ± 1.2	7.4 ± 1.0	<0.01
	62 ± 13.1	57 ± 10.9
Body weight change (kg)	0.5 ± 4.1	0.8 ± 3.5	0.06
Total cholesterol (mg/dl)
Baseline	182 ± 33	183 ± 35	N.S.
Average over 1 year	176 ± 27	184 ± 31	0.08
Triglyceride (mg/dl)
Baseline	120 ± 65	145 ± 106	N.S.
Average over 1 year	120 ± 50	154 ± 101	0.09
HDL cholesterol (mg/dl)
Baseline	56 ± 14	53 ± 15	N.S.
Average over 1 year	55 ± 13	53 ± 14	N.S.
LDL cholesterol (mg/dl)
Baseline	98 ± 27	101 ± 27	N.S.
Average over 1 year	95 ± 19	100 ± 23	N.S.

BMI: body mass index; LDL: low-density lipoprotein; HDL: high-density lipoprotein; N.S.: not significant. Data are described as mean ± SD.